For Healthcare Professionals

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors


About the study

ADG126, ADG126 in Combination with anti-PD1 antibody, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors .

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion criteria

  1. Adults ≥18 years of age.
  2. ECOG performance status 0 or 1.
  3. Estimated life expectancy of more than 12 weeks .
  4. Patients with advanced or metastatic solid tumors, confirmed by histologically or pathologically documented, who have progressed after all standard therapies, or for whom no further standard therapy exists.
  5. At least 1 measurable lesion at baseline according to the definition of RECIST v1.1.
  6. Adequate organ function.
  7. Meets the additional tumor type requirements as specified in Protocol.


Exclusion Criteria:

  1. Treatment with any investigational drug within washout period.
  2. Major trauma or major surgery within 4 weeks prior to first dose of study drug(s)
  3. History of significant immune-mediated AE.
  4. Central nervous system (CNS) disease involvement.
  5. Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC)/bone marrow (BM) transplantation
  6. Clinically significant cardiac disease.
  7. Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.

Patients who received:

  1. A COVID-19 vaccine within 7 days of Cycle 1 Day 1.
  2. Live vaccines or live-attenuated vaccines within 28 days prior to Cycle 1 Day 1.
  3. Known active infection of HBV/BCV/HIV.
  4. Patients requiring systemic treatment with corticosteroids or other immunosuppressive medications (>10 mg/day prednisone or equivalent).
  5. Second primary malignancy not in remission for greater than 3 years.
  6. History(within the last 5 years) or risk of autoimmune disease.
  7. Pregnant or breastfeeding females.
  8. Childbearing potential who does not agree to the use of contraception during the treatment period.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Advanced/Metastatic Solid Tumors

Age (in years)



Phase 1/Phase 2

Participants needed


Est. Completion Date

Dec 31, 2024

Treatment type



Adagene Inc identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.